Exagen

Yahoo Finance • 2 months ago

Exagen signals $65M–$70M revenue target for 2025 while advancing new biomarker launches

Earnings Call Insights: Exagen Inc. (XGN) Q3 2025 MANAGEMENT VIEW * CEO John Aballi reported, "Q3 was the strongest quarter in Exagen's history, driven by robust volume growth and continued execution across our commercial, scientific a... Full story

Yahoo Finance • 3 months ago

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesd... Full story

Yahoo Finance • 5 months ago

[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37... Full story

Yahoo Finance • 5 months ago

Exagen Inc. to Participate in Third Quarter Investor Conferences

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canacco... Full story

Yahoo Finance • 5 months ago

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Earnings Call Insights: Exagen Inc. (XGN) Q2 2025 MANAGEMENT VIEW * John Aballi, CEO, stated that "Q2 revenue came in at $17.2 million, representing 14% year-over-year growth and the highest quarterly revenue in company history." He hi... Full story

Yahoo Finance • 5 months ago

Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading

Exagen Inc (NASDAQ:XGN [https://www.chartmill.com/stock/quote/XGN/profile]), a commercial-stage diagnostics company specializing in autoimmune testing solutions, reported its second-quarter 2025 financial results, surpassing revenue expect... Full story

Yahoo Finance • 6 months ago

Exagen Inc. (XGN): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish the... Full story

Yahoo Finance • 6 months ago

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, J... Full story

Yahoo Finance • 7 months ago

Exagen announces resale of up to 1.15M shares

* Exagen (NASDAQ:XGN [https://seekingalpha.com/symbol/XGN]) is registering up to 1.15M shares of common stock for resale by Perceptive Credit Holdings or its affiliates. * The shares are issuable upon exercise of a warrant granted unde... Full story

Yahoo Finance • 9 months ago

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025... Full story

Yahoo Finance • 11 months ago

Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: BTIG at Snowbird:... Full story

Yahoo Finance • 2 years ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue... Full story

Yahoo Finance • 2 years ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement.... Full story

Yahoo Finance • 2 years ago

Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Heal... Full story

Yahoo Finance • 2 years ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR... Full story

Yahoo Finance • 2 years ago

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which... Full story

Yahoo Finance • 3 years ago

Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years

Exagen Inc. (NASDAQ:XGN) shareholders will doubtless be very grateful to see the share price up 43% in the last month. But only the myopic could ignore the astounding decline over three years. To wit, the share price sky-dived 73% in that... Full story

Yahoo Finance • 3 years ago

Exagen Inc. Reports First Quarter 2023 Results

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023. First Quarter Highlights: Deliv... Full story

Yahoo Finance • 3 years ago

Mindera Health™ Announces Change to Executive Leadership Team

San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.  The company has announced ind... Full story

Yahoo Finance • 3 years ago

Q4 2022 Exagen Inc Earnings Call

Participants John Aballi; CEO, President & Director; Exagen Inc. Kamal Adawi; CFO & Corporate Secretary; Exagen Inc. Ryan Douglas; Investors Relations Officer; Exagen Inc. Andrew Frederick Brackmann; Research Analyst; William Blair & C... Full story